In 1993, de Rossi and colleagues distinguished three groups of CLL patients, depending on either high, intermediate or low CD44 surface expression, defined in relation to the CD44 expression on T-cells. This evidence concerns the gene CD44 and B-cell chronic lymphocytic leukemia.